Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SOPHiA GENETICS (SOPH) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for SOPHiA GENETICS (SOPH) over the last 6 years, with Q3 2025 value amounting to $81.6 million.

  • SOPHiA GENETICS's Cash & Equivalents fell 1480.05% to $81.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.6 million, marking a year-over-year decrease of 1480.05%. This contributed to the annual value of $123.3 million for FY2024, which is 2359.13% down from last year.
  • According to the latest figures from Q3 2025, SOPHiA GENETICS's Cash & Equivalents is $81.6 million, which was down 1480.05% from $94.8 million recorded in Q2 2025.
  • In the past 5 years, SOPHiA GENETICS's Cash & Equivalents ranged from a high of $210.0 million in Q3 2021 and a low of $42.5 million during Q2 2021
  • Moreover, its 5-year median value for Cash & Equivalents was $132.8 million (2023), whereas its average is $128.9 million.
  • As far as peak fluctuations go, SOPHiA GENETICS's Cash & Equivalents surged by 32107.23% in 2022, and later plummeted by 5026.44% in 2024.
  • Over the past 5 years, SOPHiA GENETICS's Cash & Equivalents (Quarter) stood at $193.0 million in 2021, then changed by 0.0% to $193.0 million in 2022, then dropped by 16.41% to $161.3 million in 2023, then tumbled by 50.26% to $80.2 million in 2024, then grew by 1.73% to $81.6 million in 2025.
  • Its last three reported values are $81.6 million in Q3 2025, $94.8 million for Q2 2025, and $68.5 million during Q1 2025.